* eFFECTOR Therapeutics Inc EFTR.OQ reported a quarterly
adjusted loss of $2.16 per share for the quarter ended in
January, higher than the same quarter last year, when the
company reported EPS of $-6.00. The mean expectation of
two analysts for the quarter was for a loss of $2.16 per share.
Wall Street expected results to range from $-2.35 to $-1.98 per
share.
* Reported revenue was zero; analysts expected zero.
* eFFECTOR Therapeutics Inc's reported EPS for the quarter
was a
loss of $2.16.
* The company reported a quarterly loss of $8.83 million.
* eFFECTOR Therapeutics Inc shares had fallen by 85.5% this
quarter and lost 82.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 13.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is "buy."
Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $11.00
This summary was machine generated from LSEG data May 9 at 10:23
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -2.16 -2.16 Met
Dec. 31 2023 -1.65 -3.42 Missed
Sep. 30 2023 -3.08 -3.25 Missed
Jun. 30 2023 -4.94 -4.25 Beat